Autor: |
Zhang W; State Key Laboratory of Vaccines for Infectious Diseases, Xiang-An Biomedicine Laboratory, School of Public Health, Xiamen University, China. rocque@xmu.edu.cn.; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, China., Zhu M; State Key Laboratory of Vaccines for Infectious Diseases, Xiang-An Biomedicine Laboratory, School of Public Health, Xiamen University, China. rocque@xmu.edu.cn.; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, China., Liu X; Xiamen Yan Palace Seelong Biotechnology Co., Ltd, Xiamen 361100, China. 23095216@qq.com., Que M; Xiamen Yan Palace Seelong Biotechnology Co., Ltd, Xiamen 361100, China. 23095216@qq.com., Dekyi K; State Key Laboratory of Vaccines for Infectious Diseases, Xiang-An Biomedicine Laboratory, School of Public Health, Xiamen University, China. rocque@xmu.edu.cn.; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, China., Zheng L; State Key Laboratory of Vaccines for Infectious Diseases, Xiang-An Biomedicine Laboratory, School of Public Health, Xiamen University, China. rocque@xmu.edu.cn.; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, China., Zhang Y; State Key Laboratory of Vaccines for Infectious Diseases, Xiang-An Biomedicine Laboratory, School of Public Health, Xiamen University, China. rocque@xmu.edu.cn.; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, China., Lv Y; State Key Laboratory of Vaccines for Infectious Diseases, Xiang-An Biomedicine Laboratory, School of Public Health, Xiamen University, China. rocque@xmu.edu.cn.; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, China., Fan Q; Xiamen Yan Palace Seelong Biotechnology Co., Ltd, Xiamen 361100, China. 23095216@qq.com., Wang X; Department of Nutrition, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian Province, China. wang.xinyue@zsxmhospital.com.; Xiamen Clinical Research Center for Cancer Therapy, China., Li H; State Key Laboratory of Vaccines for Infectious Diseases, Xiang-An Biomedicine Laboratory, School of Public Health, Xiamen University, China. rocque@xmu.edu.cn.; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, China. |
Abstrakt: |
Edible bird's nest (EBN) is a traditional food known for its nourishing and functional properties and is found to be involved in anti-oxidation, anti-aging, and anti-influenza mechanisms, immune regulation, and improving cardiovascular diseases, among others. However, the potential of EBN to improve glycolipid metabolism disorders in high-fat-diet induced obesity and the underlying mechanisms remain unexplored. We examined the effects of EBN on glycolipid metabolism in obese mice fed a high-fat diet. Male C57BL/6J mice were fed a high-fat diet for 8 weeks to establish an obesity model. The obese mice were selected and divided into six groups: two model control groups (normal and high-fat diets) and four intervention groups [Neu5Ac and low-, medium-, and high-dose EBN], with 12 mice in each group. After 10 weeks of continuous gavage intervention, only mice in the high-dose EBN intervention group had lower body weight and total fat content, especially visceral fat. Meanwhile, intervention with three doses of EBN reduced serum FBG, TC, LDL, Ox-LDL, IL-1β, IL-6, and TNF-α levels and increased serum HDL levels and energy expenditure. Using the high dosage as a paradigm, EBN intervention increased the sialic acid content in LDL, decreased TMAO in the liver, and increased GLP-1 levels in sera. EBN increased the colonic abundances of Akkermansia , Lactobacillus , and Desulfovibrio and reduced those of Lysinibacillus and Bacillus . The changes in the microbial community contribute to increasing colonic bile acids, reducing lipopolysaccharide synthesis to protect the intestinal barrier, and lowering inflammation levels. Changes were also observed in colonic transcripts and metabolites and liver gene transcripts and metabolites, which were mainly enriched in pathways of glycolipid metabolism, immune function amelioration, inflammatory signal mitigation, circadian rhythm, bile acid metabolism and insulin resistance. Therefore, EBN may enhance the gut microbiota and intestinal immunity, relieve chronic inflammation levels in serum, improve antioxidant capacity and circadian rhythm in the liver, promote bile acid metabolism, and decrease lipid absorption and lipid synthesis via the gut-liver axis. Consequently, this may reduce blood lipid and fat accumulation as well as improve islet function and reduce blood glucose levels. |